propranolol has been researched along with Hepatic Encephalopathy in 25 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Hepatic Encephalopathy: A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to investigate the association between propranolol treatment and outcomes for cirrhotic patients with hepatic encephalopathy." | 7.96 | Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy. ( Chen, PH; Chen, YJ; Chou, YC; Hou, MC; Huang, YH; Huo, TI; Kao, WY; Lee, FY; Lee, KC; Lee, PC; Lin, HC; Su, CW; Wu, JC, 2020) |
| "A 52-year-old woman with primary biliary cirrhosis who had never had hepatic coma developed it while taking propranolol." | 7.67 | Does propranolol precipitate hepatic encephalopathy? ( Wiesner, RH, 1986) |
| "When propranolol was administered to patients with alcoholic cirrhosis and marginal liver function, as reflected by ammonia levels above 60 microM, it caused a significant increase in ammonia levels in arterialized-venous and arterial, but not in venous, blood (p less than 0." | 6.66 | Venous, arterial, and arterialized-venous blood ammonia levels and their relationship to hepatic encephalopathy after propranolol. ( Lieber, CS; Snady, H, 1988) |
| "In contrast, auditory hallucinations are uncommon in chronic liver disease." | 5.62 | Propranolol-induced hallucinations mimicking encephalopathy in a patient with liver cirrhosis. ( Al-Dury, S; Hedenström, P; Molinaro, A, 2021) |
| " First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome." | 5.41 | Diagnosis and Management of Cirrhosis and Its Complications: A Review. ( Parikh, ND; Tapper, EB, 2023) |
| " We aimed to investigate the association between propranolol treatment and outcomes for cirrhotic patients with hepatic encephalopathy." | 3.96 | Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy. ( Chen, PH; Chen, YJ; Chou, YC; Hou, MC; Huang, YH; Huo, TI; Kao, WY; Lee, FY; Lee, KC; Lee, PC; Lin, HC; Su, CW; Wu, JC, 2020) |
| "We report the case of a patient who developed jaundice, encephalopathy, a marked increase in serum aminotransferase activity and a decrease in prothrombin and proaccelerin levels, after 6 weeks' treatment with carbimazole and propranolol for hyperthyroidism." | 3.69 | Fulminant hepatitis after carbimazole and propranolol administration. ( Banc, P; Coste, V; Epeirier, JM; Larrey, D; Michel, H; Pageaux, GP; Perrigault, PF, 1996) |
| "A 52-year-old woman with primary biliary cirrhosis who had never had hepatic coma developed it while taking propranolol." | 3.67 | Does propranolol precipitate hepatic encephalopathy? ( Wiesner, RH, 1986) |
| "Hepatic encephalopathy was observed more often in the TIPS group (40." | 2.70 | Endoscopic variceal ligation plus propranolol vs. transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. ( Hansmann, J; Richter, GM; Sauer, P; Stiehl, A; Stremmel, W, 2002) |
| "The incidence of clinically significant hepatic encephalopathy after 1 year was higher in the shunt group (36% vs 18%, p = 0." | 2.68 | Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. ( Blum, HE; Deibert, P; Geiger, R; Haag, K; Hauenstein, KH; Keller, W; Ochs, A; Olschewski, M; Rössle, M; Siegerstetter, V; Stiepak, C, 1997) |
| "Hepatic encephalopathy was observed in 29% of the patients in the TIPS group and in 13% of those in the ES group (P = 0." | 2.68 | Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. ( Benz, C; Richter, GM; Sauer, P; Stiehl, A; Stremmel, W; Theilmann, L, 1997) |
| "When propranolol was administered to patients with alcoholic cirrhosis and marginal liver function, as reflected by ammonia levels above 60 microM, it caused a significant increase in ammonia levels in arterialized-venous and arterial, but not in venous, blood (p less than 0." | 2.66 | Venous, arterial, and arterialized-venous blood ammonia levels and their relationship to hepatic encephalopathy after propranolol. ( Lieber, CS; Snady, H, 1988) |
| "Frequently, relevant liver fibrosis is diagnosed by non-invasive methods (e." | 2.58 | [Management of compensated liver cirrhosis 2018 - Evidence based prophylactic measures]. ( Benten, D; Karkmann, K; Kluwe, J; Piecha, F; Rünzi, AC; Schulz, L; von Wulffen, M; Wege, H, 2018) |
| "The best results obtained in treatment of portal hypertension were: esophagogastric devascularization and splenectomy (EGDS), although risk of rebleeding persists; classical (proximal) splenorenal shunt (SRS) should be abandoned; distal splenorenal shunt may complicate with hepatic encephalopathy, although later and in a lower percentage than in SRS." | 2.38 | Portal hypertension in schistosomiasis: pathophysiology and treatment. ( Da Silva, LC, 1992) |
| "In contrast, auditory hallucinations are uncommon in chronic liver disease." | 1.62 | Propranolol-induced hallucinations mimicking encephalopathy in a patient with liver cirrhosis. ( Al-Dury, S; Hedenström, P; Molinaro, A, 2021) |
| "Ascites, variceal bleeding, hepatic encephalopathy, and hepatorenal syndrome are among the complications you are likely to encounter when caring for a patient with cirrhosis." | 1.42 | Cirrhosis complications: keeping them under control. ( Eliacin, I; Kashan, S; Minor, SE; Whisenant, EB, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (32.00) | 18.7374 |
| 1990's | 4 (16.00) | 18.2507 |
| 2000's | 3 (12.00) | 29.6817 |
| 2010's | 6 (24.00) | 24.3611 |
| 2020's | 4 (16.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tapper, EB | 1 |
| Parikh, ND | 1 |
| Lee, PC | 1 |
| Chen, YJ | 1 |
| Chou, YC | 1 |
| Lee, KC | 1 |
| Chen, PH | 1 |
| Kao, WY | 1 |
| Huang, YH | 1 |
| Huo, TI | 1 |
| Lin, HC | 1 |
| Hou, MC | 1 |
| Lee, FY | 1 |
| Wu, JC | 1 |
| Su, CW | 1 |
| Al-Dury, S | 1 |
| Molinaro, A | 1 |
| Hedenström, P | 1 |
| Díaz-Fontenla, F | 1 |
| Castillo-Pradillo, M | 1 |
| Díaz-Gómez, A | 1 |
| Ibañez-Samaniego, L | 1 |
| Gancedo, P | 1 |
| Guzmán-de-Villoria, JA | 1 |
| Fernández-García, P | 1 |
| Bañares-Cañizares, R | 1 |
| García-Martínez, R | 1 |
| Lv, Y | 1 |
| Qi, X | 1 |
| He, C | 1 |
| Wang, Z | 1 |
| Yin, Z | 1 |
| Niu, J | 1 |
| Guo, W | 1 |
| Bai, W | 1 |
| Zhang, H | 1 |
| Xie, H | 1 |
| Yao, L | 1 |
| Wang, J | 1 |
| Li, T | 1 |
| Wang, Q | 1 |
| Chen, H | 1 |
| Liu, H | 1 |
| Wang, E | 1 |
| Xia, D | 1 |
| Luo, B | 1 |
| Li, X | 1 |
| Yuan, J | 1 |
| Han, N | 1 |
| Zhu, Y | 1 |
| Xia, J | 1 |
| Cai, H | 1 |
| Yang, Z | 1 |
| Wu, K | 1 |
| Fan, D | 1 |
| Han, G | 1 |
| Karkmann, K | 1 |
| Piecha, F | 1 |
| Rünzi, AC | 1 |
| Schulz, L | 1 |
| von Wulffen, M | 1 |
| Benten, D | 1 |
| Kluwe, J | 1 |
| Wege, H | 1 |
| Villanueva, C | 1 |
| Albillos, A | 1 |
| Genescà, J | 1 |
| Garcia-Pagan, JC | 3 |
| Calleja, JL | 1 |
| Aracil, C | 1 |
| Bañares, R | 2 |
| Morillas, RM | 1 |
| Poca, M | 1 |
| Peñas, B | 1 |
| Augustin, S | 1 |
| Abraldes, JG | 2 |
| Alvarado, E | 1 |
| Torres, F | 1 |
| Bosch, J | 3 |
| Minor, SE | 1 |
| Eliacin, I | 1 |
| Kashan, S | 1 |
| Whisenant, EB | 1 |
| Zhang, M | 1 |
| Wang, G | 1 |
| Zhao, L | 1 |
| Wu, Z | 1 |
| Zhang, W | 1 |
| Zhang, C | 1 |
| Sauer, P | 2 |
| Hansmann, J | 1 |
| Richter, GM | 2 |
| Stremmel, W | 2 |
| Stiehl, A | 2 |
| Tarantino, I | 1 |
| Turnes, J | 1 |
| Rodés, J | 1 |
| Reding, P | 1 |
| Tarver, D | 1 |
| Walt, RP | 1 |
| Dunk, AA | 2 |
| Jenkins, WJ | 1 |
| Sherlock, S | 1 |
| Watson, P | 1 |
| Hayes, JR | 1 |
| Epeirier, JM | 1 |
| Pageaux, GP | 1 |
| Coste, V | 1 |
| Perrigault, PF | 1 |
| Banc, P | 1 |
| Larrey, D | 1 |
| Michel, H | 1 |
| Rössle, M | 1 |
| Deibert, P | 1 |
| Haag, K | 1 |
| Ochs, A | 1 |
| Olschewski, M | 1 |
| Siegerstetter, V | 1 |
| Hauenstein, KH | 1 |
| Geiger, R | 1 |
| Stiepak, C | 1 |
| Keller, W | 1 |
| Blum, HE | 1 |
| Theilmann, L | 1 |
| Benz, C | 1 |
| Escorsell, A | 1 |
| Gilabert, R | 1 |
| Moitinho, E | 1 |
| Piqueras, B | 1 |
| Bru, C | 1 |
| Echenagusia, A | 1 |
| Granados, A | 1 |
| Da Silva, LC | 1 |
| Calès, P | 1 |
| Moore, J | 1 |
| Symon, A | 1 |
| Dickie, A | 1 |
| Sinclair, TS | 1 |
| Mowat, NA | 1 |
| Brunt, PW | 1 |
| Snady, H | 1 |
| Lieber, CS | 1 |
| Wiesner, RH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Treatment Combined With Propranolol for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis: A Randomized Controlled Trial[NCT01326949] | 52 participants (Actual) | Interventional | 2011-05-31 | Completed | |||
| A Novel Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108)[NCT05100485] | 1,000 participants (Actual) | Observational | 2022-01-01 | Completed | |||
| Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension[NCT01059396] | Phase 4 | 201 participants (Actual) | Interventional | 2010-01-28 | Completed | ||
| CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease: an International Multicenter Study (CHESS2102)[NCT04975477] | 1,000 participants (Anticipated) | Observational | 2021-07-16 | Not yet recruiting | |||
| Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy[NCT01851252] | Phase 1 | 19 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for propranolol and Hepatic Encephalopathy
| Article | Year |
|---|---|
Diagnosis and Management of Cirrhosis and Its Complications: A Review.
Topics: Adult; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Enc | 2023 |
[Management of compensated liver cirrhosis 2018 - Evidence based prophylactic measures].
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Germany; Hepatic Encephalop | 2018 |
Portal hypertension in schistosomiasis: pathophysiology and treatment.
Topics: Animals; Cricetinae; Esophageal and Gastric Varices; Follow-Up Studies; Gastrointestinal Hemorrhage; | 1992 |
8 trials available for propranolol and Hepatic Encephalopathy
| Article | Year |
|---|---|
Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial.
Topics: Adult; Combined Modality Therapy; Esophageal and Gastric Varices; Female; Follow-Up Studies; Gastroi | 2018 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
Endoscopic variceal ligation plus propranolol vs. transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Esophageal and Gastric Varices; Female; Hepatic Encephalop | 2002 |
Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Embolization, Therapeutic; Endoscopy; Eso | 1997 |
Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding.
Topics: Adult; Aged; Esophageal and Gastric Varices; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; | 1997 |
TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Aged; Drug Therapy, Combination; Female; Follow-Up Studies; Health Care | 2002 |
The effects of propranolol on hepatic encephalopathy in patients with cirrhosis and portal hypertension.
Topics: Adult; Aged; Double-Blind Method; Electroencephalography; Female; Hepatic Encephalopathy; Humans; Hy | 1988 |
Venous, arterial, and arterialized-venous blood ammonia levels and their relationship to hepatic encephalopathy after propranolol.
Topics: Ammonia; Arteries; Hepatic Encephalopathy; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Prop | 1988 |
14 other studies available for propranolol and Hepatic Encephalopathy
| Article | Year |
|---|---|
Low dose of propranolol treatment is associated with better survival in cirrhotic patients with hepatic encephalopathy.
Topics: Adrenergic beta-Antagonists; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Proportional Hazards M | 2020 |
KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.
Topics: Adrenergic beta-Antagonists; Ammonia; Anti-Bacterial Agents; Carvedilol; Disaccharides; Endoscopy, G | 2020 |
Propranolol-induced hallucinations mimicking encephalopathy in a patient with liver cirrhosis.
Topics: Hallucinations; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Propranolol; Rifaximin | 2021 |
Refractory hepatic encephalopathy in a patient with hypothyroidism: Another element in ammonia metabolism.
Topics: Adrenergic beta-Antagonists; Alcoholism; Ammonia; Antithyroid Agents; Brain; Carbimazole; Diagnosis, | 2017 |
Cirrhosis complications: keeping them under control.
Topics: Antihypertensive Agents; Ascites; Diuretics; Furosemide; Hemorrhage; Hepatic Encephalopathy; Humans; | 2015 |
Second prophylaxis of variceal bleeding in cirrhotic patients with a high HVPG.
Topics: Adult; Aged; China; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hepatic Enc | 2016 |
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.
Topics: Antihypertensive Agents; Ascites; Bacterial Infections; Cohort Studies; Drug Therapy, Combination; F | 2003 |
Risk of hepatic encephalopathy in patients taking propranolol for portal hypertension.
Topics: Hepatic Encephalopathy; Humans; Hypertension, Portal; Propranolol; Risk | 1982 |
Portal hypertension, propranolol, and hepatic encephalopathy.
Topics: Hepatic Encephalopathy; Humans; Hypertension, Portal; Liver Cirrhosis; Portacaval Shunt, Surgical; P | 1982 |
Precipitation of hepatic encephalopathy by propranolol in cirrhosis.
Topics: Aged; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; H | 1983 |
Cirrhosis, hepatic encephalopathy, and propranolol.
Topics: Hepatic Encephalopathy; Humans; Liver Cirrhosis; Male; Propranolol | 1983 |
Fulminant hepatitis after carbimazole and propranolol administration.
Topics: Adrenergic beta-Antagonists; Alanine Transaminase; Antithyroid Agents; Aspartate Aminotransferases; | 1996 |
[Propranolol and the risk of hepatic encephalopathy in liver cirrhosis].
Topics: Ammonia; Cerebrovascular Circulation; Electroencephalography; Esophageal and Gastric Varices; Heart | 1989 |
Does propranolol precipitate hepatic encephalopathy?
Topics: Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; | 1986 |